CHMP positive for Kevzara (sarilumab) to treat polymyalgia rheumatica – Sanofi

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Kevzara. The marketing authorisation holder for this medicinal product is Sanofi Winthrop Industrie.

The CHMP adopted a new indication as follows: Polymyalgia rheumatica; Kevzara is indicated for the treatment of polymyalgia rheumatica (PMR) in adult patients who have had an inadequate response to corticosteroids or who experience a relapse during corticosteroid taper.